Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pratley

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Annals of the New York Academy of Sciences|December 12, 2024
Diabetes and cardiovascular disease in older adultsAnika Bilal, Richard Pratley
Diabetes & Vascular Disease Research|October 2, 2007
The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?Vanitha Singaram, Richard Pratley
Current Diabetes Reports|February 22, 2011
Alternative and complementary treatments for metabolic syndromeMariya Power, Richard Pratley
Current Diabetes Reports|March 9, 2006
Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetesSusanne Trost, Richard Pratley, Burton Sobel
Current Opinion in Gastroenterology|July 5, 2024
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?Richard Pratley, Zeb I Saeed, Anna Casu
Diabetes, Obesity & Metabolism|April 9, 2020
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programmeTina K Thethi, Richard Pratley, Juris J Meier
The American Journal of Medicine|January 6, 2024
Chapter 1: The Burden of Heart FailureRichard Pratley, Xuan Guan, Richard J Moro, et al.
Pharmaceutical Medicine|January 15, 2020
Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin DataAngelo Del Parigi, Wenbo Tang, Dacheng Liu, et al.
The Journal of Clinical Endocrinology and Metabolism|December 18, 2021
An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regressionIldiko Lingvay, Robert Bauer, James Baker-Knight, et al.
BMJ Case Reports|June 17, 2017
Postgastric bypass hypoglycaemia in a patient with end-stage renal disease: a diagnostic and management pitfallSameen Khalid, Anika Bilal, F N U Asad-Ur-Rahman, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Annals of the New York Academy of Sciences|December 12, 2024
Diabetes and cardiovascular disease in older adultsAnika Bilal, Richard Pratley
Diabetes & Vascular Disease Research|October 2, 2007
The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?Vanitha Singaram, Richard Pratley
Current Diabetes Reports|February 22, 2011
Alternative and complementary treatments for metabolic syndromeMariya Power, Richard Pratley
Current Diabetes Reports|March 9, 2006
Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetesSusanne Trost, Richard Pratley, Burton Sobel
Current Opinion in Gastroenterology|July 5, 2024
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?Richard Pratley, Zeb I Saeed, Anna Casu
Diabetes, Obesity & Metabolism|April 9, 2020
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programmeTina K Thethi, Richard Pratley, Juris J Meier
The American Journal of Medicine|January 6, 2024
Chapter 1: The Burden of Heart FailureRichard Pratley, Xuan Guan, Richard J Moro, et al.
Pharmaceutical Medicine|January 15, 2020
Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin DataAngelo Del Parigi, Wenbo Tang, Dacheng Liu, et al.
The Journal of Clinical Endocrinology and Metabolism|December 18, 2021
An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regressionIldiko Lingvay, Robert Bauer, James Baker-Knight, et al.
BMJ Case Reports|June 17, 2017
Postgastric bypass hypoglycaemia in a patient with end-stage renal disease: a diagnostic and management pitfallSameen Khalid, Anika Bilal, F N U Asad-Ur-Rahman, et al.
Pageof 7